ArticleJournal for immunotherapy of cancer2021

Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.

Chrisann Kyi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.